Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study
Posted innews OB/GYN & Women’s Health Oncology

Evaluating Androgen Receptor Inhibition Combined with Hormonal Therapies in Recurrent Adult-Type Ovarian Granulosa Cell Tumor: Insights from a Phase II Study

A Phase II trial assessed the combination of darolutamide, leuprolide acetate, and exemestane in recurrent adult-type ovarian granulosa cell tumor, showing limited objective response but clinically meaningful progression-free survival without severe toxicity.
Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4

End-stage metabolic dysfunction-associated steatohepatitis (MASH) features profound disruptions in thyroid hormone metabolism across liver, portal, and systemic compartments, with the hepatic T3 level and systemic T3/rT3 ratio serving as sensitive diagnostic biomarkers and systemic T4 correlating with disease severity.
Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence
Posted inClinical Updates Diabetes & Endocrinology news

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.